Literature DB >> 8846920

Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys.

L A Godley1, J B Kopp, M Eckhaus, J J Paglino, J Owens, H E Varmus.   

Abstract

Transgenic mice expressing wild-type murine p53 under the control of the mouse mammary tumor virus long terminal repeat (MMTV LTR) undergo progressive renal failure due to abnormal kidney development. Similar phenotypes are observed in two transgenic lines that express wild-type p53 within the ureteric bud but not in transgenic animals expressing a dominant-negative p53 mutant allele. Defective differentiation of the ureteric bud, as evidenced by altered marker expression during development, accompanies expression of the p53 transgene. At E17.5-18.5, metanephric mesenchymal cells undergo high rates of apoptosis, and fewer cells than normal are converted to tubular epithelium. As a result, p53 transgenic kidneys grow to only half of their expected size and contain about half of the normal number of nephrons, with compensatory hypertrophy of the glomeruli. In this setting, rather than arrest the cell cycle or induce apoptosis directly, abnormally high levels of wild-type p53 appear to alter cellular differentiation in embryonic ureteric buds and cause secondary effects (apoptosis and inefficient conversion to epithelium) in the adjacent undifferentiated mesenchyme.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8846920     DOI: 10.1101/gad.10.7.836

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  40 in total

Review 1.  Mouse models of p53 functions.

Authors:  Guillermina Lozano
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

2.  Tight regulation of p53 activity by Mdm2 is required for ureteric bud growth and branching.

Authors:  Sylvia Hilliard; Karam Aboudehen; Xiao Yao; Samir S El-Dahr
Journal:  Dev Biol       Date:  2011-03-21       Impact factor: 3.582

Review 3.  Prenatal programming-effects on blood pressure and renal function.

Authors:  Eberhard Ritz; Kerstin Amann; Nadezda Koleganova; Kerstin Benz
Journal:  Nat Rev Nephrol       Date:  2011-02-01       Impact factor: 28.314

4.  The extracellular domain of Notch2 increases its cell-surface abundance and ligand responsiveness during kidney development.

Authors:  Zhenyi Liu; Shuang Chen; Scott Boyle; Yu Zhu; Andrew Zhang; David R Piwnica-Worms; Ma Xenia G Ilagan; Raphael Kopan
Journal:  Dev Cell       Date:  2013-06-24       Impact factor: 12.270

5.  Telomere shortening in neural stem cells disrupts neuronal differentiation and neuritogenesis.

Authors:  Sacri R Ferrón; M Angeles Marqués-Torrejón; Helena Mira; Ignacio Flores; Kerrie Taylor; María A Blasco; Isabel Fariñas
Journal:  J Neurosci       Date:  2009-11-18       Impact factor: 6.167

6.  p53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding.

Authors:  K C Lee; A J Crowe; M C Barton
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

7.  Differences in p53 and Bcl-2 expression in relation to cell proliferation during the development of human embryos.

Authors:  V Lichnovský; Z Kolár; P Murray; A Hlobilková; D Cernochová; E Pospísilová; B Vojtĕsek; R Nenutil
Journal:  Mol Pathol       Date:  1998-06

8.  Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure.

Authors:  J Megyesi; R L Safirstein; P M Price
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

9.  Increased p53 activity does not accelerate telomere-driven ageing.

Authors:  Isabel García-Cao; Marta García-Cao; Antonia Tomás-Loba; Juan Martín-Caballero; Juana M Flores; Peter Klatt; María A Blasco; Manuel Serrano
Journal:  EMBO Rep       Date:  2006-03-31       Impact factor: 8.807

Review 10.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.